Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Julg

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Biorxiv : the Preprint Server for Biology|June 9, 2020
Predicting the Immunogenicity of T cell epitopes: From HIV to SARS-CoV-2Ang Gao, Zhilin Chen, Florencia Pereyra Segal, et al.
Nucleic Acids Research|March 13, 2016
Repurposing the CRISPR-Cas9 system for targeted DNA methylationAleksandar Vojta, Paula Dobrinić, Vanja Tadić, et al.
Plos One|February 21, 2012
Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South AfricaBoris Julg, Danielle Poole, Musie Ghebremichael, et al.
Immunity|June 14, 2024
Longitudinal humoral analysis in RSV-infected infants identifies pre-existing RSV strain-specific G and evolving cross-reactive F antibodiesNadège Nziza, Wonyeong Jung, Maanasa Mendu, et al.
Nature Communications|December 18, 2025
Minor SHIV variants abrogate protective efficacy of broadly neutralizing antibodies in rhesus macaquesVictoria E K Walker-Sperling, Joseph Nkolola, Jinyan Liu, et al.
Journal of Virology|November 28, 2025
The functional antibody landscape in HIV post-treatment controllers is heterogeneousNicholas E Webb, Matthew J Gorman, Lily J Parker, et al.
Open Forum Infectious Diseases|December 10, 2021
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19Robert W Finberg, Madiha Ashraf, Boris Julg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue ReservoirsChuangqi Wang, Timothy E Schlub, Wen Han Yu, et al.
Elife|April 12, 2021
Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadthDeniz Cizmeci, Giuseppe Lofano, Evan Rossignol, et al.
Plos Pathogens|September 6, 2022
Evolution of functional antibodies following acute Epstein-Barr virus infectionChristina B Karsten, Yannic C Bartsch, Sally A Shin, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Biorxiv : the Preprint Server for Biology|June 9, 2020
Predicting the Immunogenicity of T cell epitopes: From HIV to SARS-CoV-2Ang Gao, Zhilin Chen, Florencia Pereyra Segal, et al.
Nucleic Acids Research|March 13, 2016
Repurposing the CRISPR-Cas9 system for targeted DNA methylationAleksandar Vojta, Paula Dobrinić, Vanja Tadić, et al.
Plos One|February 21, 2012
Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South AfricaBoris Julg, Danielle Poole, Musie Ghebremichael, et al.
Immunity|June 14, 2024
Longitudinal humoral analysis in RSV-infected infants identifies pre-existing RSV strain-specific G and evolving cross-reactive F antibodiesNadège Nziza, Wonyeong Jung, Maanasa Mendu, et al.
Nature Communications|December 18, 2025
Minor SHIV variants abrogate protective efficacy of broadly neutralizing antibodies in rhesus macaquesVictoria E K Walker-Sperling, Joseph Nkolola, Jinyan Liu, et al.
Journal of Virology|November 28, 2025
The functional antibody landscape in HIV post-treatment controllers is heterogeneousNicholas E Webb, Matthew J Gorman, Lily J Parker, et al.
Open Forum Infectious Diseases|December 10, 2021
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19Robert W Finberg, Madiha Ashraf, Boris Julg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue ReservoirsChuangqi Wang, Timothy E Schlub, Wen Han Yu, et al.
Elife|April 12, 2021
Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadthDeniz Cizmeci, Giuseppe Lofano, Evan Rossignol, et al.
Plos Pathogens|September 6, 2022
Evolution of functional antibodies following acute Epstein-Barr virus infectionChristina B Karsten, Yannic C Bartsch, Sally A Shin, et al.
Pageof 7